Press coverage about Zogenix (NASDAQ:ZGNX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zogenix earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.7791535275996 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Zogenix (NASDAQ:ZGNX) traded down $1.00 during mid-day trading on Friday, hitting $37.00. The stock had a trading volume of 394,215 shares, compared to its average volume of 646,670. Zogenix has a 1-year low of $8.05 and a 1-year high of $43.35. The stock has a market capitalization of $1,170.00, a price-to-earnings ratio of -8.43 and a beta of 1.78. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.71.
Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($1.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.16). Zogenix had a negative return on equity of 99.61% and a negative net margin of 309.76%. equities analysts expect that Zogenix will post -4.45 earnings per share for the current year.
Several analysts have recently weighed in on ZGNX shares. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Mizuho reiterated a “buy” rating and set a $51.00 target price on shares of Zogenix in a research report on Wednesday, November 8th. Zacks Investment Research upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, January 27th. JMP Securities began coverage on Zogenix in a report on Monday, November 27th. They issued an “outperform” rating and a $56.00 price objective for the company. Finally, ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Friday. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $42.67.
In other Zogenix news, Director Roger Hawley sold 11,797 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $37.02, for a total value of $436,724.94. Following the completion of the transaction, the director now directly owns 105,575 shares of the company’s stock, valued at $3,908,386.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Bradley S. Galer bought 1,346 shares of Zogenix stock in a transaction dated Wednesday, December 13th. The shares were acquired at an average cost of $36.59 per share, with a total value of $49,250.14. The disclosure for this purchase can be found here. Insiders own 5.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zogenix (NASDAQ:ZGNX) Given Daily News Impact Rating of 0.07” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/02/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-zogenix-zgnx-stock-price.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.